SCHEMBL718874

SCHEMBL718874

O=C(N1CCc2cc3ncc(=O)[nH]c3cc2CC1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.43
ESR2 Q92731 4/20 0.43
MAPKAPK2 P49137 1/20 0.37
RPS6KA3 P51812 1/20 0.37
CSNK2A1 P68400 1/20 0.37
PLK3 Q9H4B4 1/20 0.37
HSD11B1 P28845 2/20 0.36
CNR1 P21554 1/20 0.36
SMYD3 Q9H7B4 3/20 0.34
HPGDS O60760 1/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MGLL Q99685 1/20 0.33
CYP11B2 P19099 2/20 0.33
RBP4 P02753 1/20 0.32
HRH4 Q9H3N8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL720041 0.79 SMYD3 (0.42) MAPKAPK2RPS6KA3CSNK2A1PLK3HSD11B1
SCHEMBL719752 0.77 ESR1 (0.48) ESR1ESR2CNR1ALDH1A1KDM4E
SCHEMBL719748 0.77 ESR1 (0.52) ESR1ESR2CYP11B2
SCHEMBL722449 0.74 ESR1 (0.48) ESR1ESR2ALDH1A1POLBSMN1; SMN2
SCHEMBL719782 0.72 MAPKAPK2 (0.46) MAPKAPK2RPS6KA3CSNK2A1PLK3HSD11B1
SCHEMBL3715395 0.72 ESR1 (0.48) ESR1ESR2CYP11B2
SCHEMBL719456 0.69 ESR1 (0.56) ESR1ESR2CYP11B2
SCHEMBL3714342 0.69 ESR1 (0.37) ESR1ESR2ALDH1A1KDM4E
SCHEMBL722817 0.67 ESR1 (0.51) ESR1ESR2SMN1; SMN2CYP11B2
SCHEMBL31164747 0.67 ESR1 (0.51) ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2012-03-01 US disclosed
WO-2010096384-A2 FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS TARGACEPT, INC. (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053168-A1 FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA2, CHRNA5, CHRNA10 ESR1 1178/4885ESR2 825/4885MAPKAPK2 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.